TNF Pharmaceuticals, Inc. - Asset Resilience Ratio
TNF Pharmaceuticals, Inc. (TNFA) has an Asset Resilience Ratio of 21.02% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how TNF Pharmaceuticals, Inc.'s Asset Resilience Ratio has changed over time. Check TNFA capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down TNF Pharmaceuticals, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see TNFA company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.61 Million | 21.02% |
| Total Liquid Assets | $3.61 Million | 21.02% |
Asset Resilience Insights
- Good Liquidity Position: TNF Pharmaceuticals, Inc. maintains a healthy 21.02% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
TNF Pharmaceuticals, Inc. Industry Peers by Asset Resilience Ratio
Compare TNF Pharmaceuticals, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for TNF Pharmaceuticals, Inc. (2014–2024)
The table below shows the annual Asset Resilience Ratio data for TNF Pharmaceuticals, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 38.96% | $8.35 Million | $21.42 Million | +26.41pp |
| 2023-12-31 | 12.55% | $2.24 Million | $17.86 Million | -10.75pp |
| 2022-12-31 | 23.30% | $4.09 Million | $17.54 Million | -21.04pp |
| 2021-12-31 | 44.34% | $11.00 Million | $24.81 Million | -1.03pp |
| 2020-12-31 | 45.38% | $16.72 Million | $36.84 Million | -38.81pp |
| 2019-12-31 | 84.19% | $9.16 Million | $10.88 Million | +16.65pp |
| 2018-12-31 | 67.54% | $5.27 Million | $7.81 Million | +13.87pp |
| 2017-12-31 | 53.67% | $5.01 Million | $9.34 Million | +52.69pp |
| 2016-12-31 | 0.98% | $50.00K | $5.09 Million | -47.68pp |
| 2015-12-31 | 48.66% | $4.03 Million | $8.27 Million | -6.98pp |
| 2014-12-31 | 55.64% | $9.26 Million | $16.65 Million | -- |
About TNF Pharmaceuticals, Inc.
Q/C Technologies, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rh… Read more